Malagon Ignacio, Onkenhout Willem, Klok Margreet, Linthorst Lisa, van der Poel Petrus F H, Bovill James G, Hazekamp Mark G
Department of Anesthesia, Leiden University Medical Center, The Netherlands.
J Thorac Cardiovasc Surg. 2005 Aug;130(2):265-71. doi: 10.1016/j.jtcvs.2005.02.047.
Little attention has been paid to the effect of the systemic inflammatory response syndrome on intestinal dysfunction in the postoperative period. Several proinflammatory cytokines have been reported to increase the permeability of intestinal mucosa in vitro. We investigated the effect of dexamethasone on gut permeability in pediatric patients undergoing cardiac surgery by using the dual sugar permeability test and absorption of 2 other saccharides.
Thirty-four patients scheduled for cardiac surgery with cardiopulmonary bypass were prospectively randomized to either act as control subjects or to receive dexamethasone (1 mg . kg -1) during induction of anesthesia. Intestinal permeability was measured with 3-O-methyl-D-glucose, D-xylose, L-rhamnose, and lactulose administered orally after induction of anesthesia and 12 and 24 hours later.
Lactulose/rhamnose ratios were increased from the outset in both groups (mean 0.57 [95% confidence interval, 0.24-0.91] for the control group and 0.76 [95% confidence interval, 0.35-1.17] for patients receiving dexamethasone). Although the ratios decreased 12 hours (0.29 [95% confidence interval, 0.17-0.42]) and 24 hours later (0.17 [95% confidence interval, 0.08-0.15]) in the dexamethasone group, in the control group there was a rise at 12 hours (0.77 [95% confidence interval, 0-1.64]), with a slight reduction 24 hours later (0.46 [95% confidence interval, 0.06-0.85]).
Infants and children undergoing cardiac surgery with cardiopulmonary bypass show a significant reduction in gut permeability when dexamethasone is used during induction of anesthesia. Dexamethasone does not affect the intestinal barrier at the functional level, as assessed on the basis of 3-O-methyl-D-glucose and D-xylose absorption.
全身炎症反应综合征对术后肠道功能障碍的影响鲜受关注。有报道称,几种促炎细胞因子在体外可增加肠黏膜通透性。我们通过双糖通透性试验及另外两种糖类的吸收情况,研究了地塞米松对接受心脏手术的儿科患者肠道通透性的影响。
34例计划行体外循环心脏手术的患者被前瞻性随机分为对照组或在麻醉诱导期接受地塞米松(1 mg·kg-1)治疗。麻醉诱导后、12小时及24小时后口服3-O-甲基-D-葡萄糖、D-木糖、L-鼠李糖和乳果糖,测量肠道通透性。
两组患者乳果糖/鼠李糖比值从一开始就升高(对照组平均为0.57[95%置信区间,0.24 - 0.91],接受地塞米松治疗的患者为0.76[95%置信区间,0.35 - 1.17])。地塞米松组该比值在12小时(0.29[95%置信区间,0.17 - 0.42])和24小时后(0.17[95%置信区间,0.08 - 0.15])下降,而对照组在12小时时升高(0.77[95%置信区间,0 - 1.64]),24小时后略有下降(0.46[95%置信区间,0.06 - 0.85])。
接受体外循环心脏手术的婴幼儿在麻醉诱导期使用地塞米松时,肠道通透性显著降低。根据地塞米松对3-O-甲基-D-葡萄糖和D-木糖吸收的影响评估,其在功能水平上不影响肠道屏障。